These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 26389633)

  • 1. Marked elevation of procalcitonin in a patient with a drug related infusion reaction to rituximab.
    Robier C; Neubauer M; Reicht G
    Clin Chem Lab Med; 2016 Mar; 54(3):e101-3. PubMed ID: 26389633
    [No Abstract]   [Full Text] [Related]  

  • 2. Systemic lupus erythematosus following rituximab treatment for non-Hodgkin lymphoma.
    Soura E; Avgerinou G; Papoutsaki M; Stavropoulos P; Antoniou C
    J Dtsch Dermatol Ges; 2016 Mar; 14(3):298-301. PubMed ID: 26788717
    [No Abstract]   [Full Text] [Related]  

  • 3. New-onset psoriasis induced by rituximab therapy for non-Hodgkin lymphoma in a child.
    Kim DW; Park SK; Woo SH; Yun SK; Kim HU; Park J
    Eur J Dermatol; 2016 Apr; 26(2):190-1. PubMed ID: 26771919
    [No Abstract]   [Full Text] [Related]  

  • 4. Safety of rituximab in a patient with chronic renal failure and low-grade non-Hodgkin lymphoma.
    Chebib R; Ghorra C; Kattan J
    J Cancer Res Ther; 2015; 11(3):646. PubMed ID: 26458604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma.
    Burke JM; van der Jagt RH; Kahl BS; Wood P; Hawkins TE; MacDonald D; Hertzberg M; Simpson D; Craig M; Kolibaba K; Issa S; Munteanu M; Victor TW; Flinn IW
    Clin Lymphoma Myeloma Leuk; 2016 Apr; 16(4):182-190.e1. PubMed ID: 26875824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Late-Onset Neutropenia After Rituximab-Containing Therapy for Non-Hodgkin Lymphoma.
    Aguiar-Bujanda D; Blanco-Sánchez MJ; Hernández-Sosa M; Galván-Ruíz S; Hernández-Sarmiento S; Saura-Grau S; Bohn-Sarmiento U
    Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):761-5. PubMed ID: 26319620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin's lymphoma.
    Cho Y; Yu SJ; Cho EJ; Lee JH; Kim TM; Heo DS; Kim YJ; Yoon JH
    J Med Virol; 2016 Jun; 88(6):1010-7. PubMed ID: 26531242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for developing infusion reaction after rituximab administration in patients with B-cell non-Hodgkin's lymphoma.
    Tachi T; Yasuda M; Usui K; Umeda M; Nagaya K; Osawa T; Ichihashi A; Noguchi Y; Goto H; Kasahara S; Takahashi T; Goto C; Teramachi H
    Pharmazie; 2015 Oct; 70(10):674-7. PubMed ID: 26601425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Vaccination of patients with non-Hodgkin lymphoma under rituximab or other immunosuppressive drugs].
    Rodríguez-García J; Fernández-Santos R; García-Erce JA
    Med Clin (Barc); 2016 Jan; 146(1):43-4. PubMed ID: 25851912
    [No Abstract]   [Full Text] [Related]  

  • 10. Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin lymphoma.
    Fowler NH; Nastoupil LJ; Hagemeister FB; Neelapu SS; Fayad LE; LeBlanc D; Samaniego F; Cheah CY
    Haematologica; 2015 Nov; 100(11):e454-7. PubMed ID: 26250576
    [No Abstract]   [Full Text] [Related]  

  • 11. Retroperitoneal fibrosis due to B-cell non-Hodgkin lymphoma: Responding to rituximab!
    Alvarez Argote J; Bauer FA; Posteraro AF; Dasanu CA
    J Oncol Pharm Pract; 2016 Feb; 22(1):179-85. PubMed ID: 25013186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid infusion rituximab changing practice for patient care.
    Al Zahrani A; Ibrahim N; Al Eid A
    J Oncol Pharm Pract; 2009 Sep; 15(3):183-6. PubMed ID: 19171551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of secondary hypogammaglobulinaemia after Rituximab and Fludarabine in indolent non-Hodgkin lymphomas: A retrospective cohort study.
    De Angelis F; Tosti ME; Capria S; Russo E; D'Elia GM; Annechini G; Stefanizzi C; Foà R; Pulsoni A
    Leuk Res; 2015 Dec; 39(12):1382-8. PubMed ID: 26547259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delayed reduction in left ventricular function following treatment of non-Hodgkin's lymphoma with chemotherapy and rituximab, unrelated to acute infusion reaction.
    Kanamori H; Tsutsumi Y; Mori A; Kawamura T; Obara S; Shimoyama N; Tanaka J; Asaka M; Imamura M; Masauzi N
    Cardiology; 2006; 105(3):184-7. PubMed ID: 16490965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chlorambucil-rituximab as first-line therapy in patients affected by follicular non-Hodgkin's lymphoma: a retrospective single-centre study.
    Martinelli G; Montoro J; Vanazzi A; Andreola G; Liptrott S; Radice D; Negri M; Preda L; Pruneri G; Laszlo D
    Hematol Oncol; 2015 Dec; 33(4):129-35. PubMed ID: 25047267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab with high-dose methotrexate in primary central nervous system lymphoma.
    Kansara R; Shenkier TN; Connors JM; Sehn LH; Savage KJ; Gerrie AS; Villa D
    Am J Hematol; 2015 Dec; 90(12):1149-54. PubMed ID: 26414492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A molecular perspective on rituximab: A monoclonal antibody for B cell non Hodgkin lymphoma and other affections.
    Seyfizadeh N; Seyfizadeh N; Hasenkamp J; Huerta-Yepez S
    Crit Rev Oncol Hematol; 2016 Jan; 97():275-90. PubMed ID: 26443686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute jugular vein thrombosis during rituximab administration: Review of the literature.
    Dada R; Zekri J; Ramal B; Ahmad K
    J Oncol Pharm Pract; 2016 Feb; 22(1):165-9. PubMed ID: 25063762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [THE MECHANISMS OF ACTION OF RITUXIMAB].
    Gil'deeva GN; Kudlai DA; Luk'yanov SV
    Eksp Klin Farmakol; 2015; 78(12):51-6. PubMed ID: 27051930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of adverse events in patients receiving rapid rituximab infusion: validation of a predictive model.
    Lang DS; Fong CC
    Clin J Oncol Nurs; 2014 Feb; 18(1):89-92. PubMed ID: 24476730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.